RxDoctor Payments Data

Himasha Gunasekara

Physician Assistant · Plymouth Meeting, PANPI 1053036111

Payments from drug & device makers

$884in general payments, 2019–2025

Across 10 payments — averaging $88.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$329
  • Teva Pharmaceuticals USA, Inc.$160
  • Otsuka America Pharmaceutical, Inc.$141
  • Amneal Pharmaceuticals LLC$117
  • UCB, Inc.$114
  • Sumitomo Pharma America, Inc.$23

What the payments were for

  • Food & beverage$884100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$884 in reported general payments places this provider in the 75th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$162,667
Medicare patients
200
Services billed
1,621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin15$8,250
GemtesaVibegron19$7,487
Brimonidine Tartrate12$1,521
Rosuvastatin Calcium16$1,099
Tramadol Hcl50$932
Levothyroxine Sodium17$729
Atorvastatin Calcium45$593
Tamsulosin Hcl17$568
Gabapentin36$539
Mirtazapine23$509
Lorazepam36$498
Timolol Maleate13$412
Trazodone Hcl47$376
Amlodipine Besylate53$360
Nifedipine ErNifedipine25$354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$23$7,48719 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$117$72917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Plymouth Meeting

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →